[1]Solomon EI, Sundaram UM, Machonkin TE. Multicopper oxidases and oxygenases[J]. Chem Rev, 1996, 96(7): 2563-2606.
[2]Que EL, Domaille DW, Chang CJ. Metals in neurobiology: probing their chemistry and biology with molecular imaging[J]. Chem Rev, 2008, 108(5): 1517-1549.
[3]Gunjan D, Shalimar, Nadda N, et al. Hepatocellular carcinoma: an unusual complication of longstanding Wilson disease[J]. J Clin Exp Hepatol, 2017, 7(2): 152-154.
[4]Bock FJ, Tait S. Mitochondria as multifaceted regulators of cell death[J]. Nat Rev Mol Cell Biol, 2020, 21(2): 85-100.
[5]Tsvetkov P, Coy S, Petrova B, et al. Copper induces cell death by targeting lipoylated TCA cycle proteins[J]. Science, 2022, 375(6586): 1254-1261.
[6]Tsvetkov P, Detappe A, Cai K, et al. Mitochondrial metabolism promotes adaptation to proteotoxic stress[J]. Nat Chem Biol, 2019, 15(7): 681-689.
[7]Institute of Medicine (US) Panel on Micronutrients. Dietary reference intakes for Vitamin A, Vitamin K, arsenic, boron, chromium, copper, iodine, iron, manganese, molybdenum, nickel, silicon, vanadium, and zinc[M]. Washington (DC): National Academies Press (US), 2001.
[8]O′Halloran TV, Culotta VC. Metallochaperones, an intracellular shuttle service for metal ions[J]. J Biol Chem, 2000, 275(33): 25057-25060.
[9]Rosenzweig AC. Copper delivery by metallochaperone proteins[J]. Acc Chem Res, 2001, 34(2): 119-128.
[10]Polishchuk EV, Concilli M, Iacobacci S, et al. Wilson disease protein ATP7B utilizes lysosomal exocytosis to maintain copper homeostasis[J]. Dev Cell, 2014, 29(6): 686-700.
[11]Roelofsen H, Wolters H, Van Luyn MJ, et al. Copperinduced apical trafficking of ATP7B in polarized hepatoma cells provides a mechanism for biliary copper excretion[J]. Gastroenterology, 2000, 119(3): 782-793.
[12]Saroli PC, Schilsky ML. Clinical practice guidelines in Wilson disease[J]. Ann Transl Med, 2019, 7(Suppl 2): S65.
[13]Harvey LJ, Ashton K, Hooper L, et al. Methods of assessment of copper status in humans: a systematic review[J]. Am J Clin Nutr, 2009, 89(6): 2009S-2024S.
[14]Ren F, Logeman BL, Zhang X, et al. Xray structures of the highaffinity copper transporter Ctr1[J]. Nat Commun, 2019, 10(1): 1386.
[15]Lee J, Pena MM, Nose Y, et al. Biochemical characterization of the human copper transporter Ctr1[J]. J Biol Chem, 2002, 277(6): 4380-4387.
[16]Ohgami RS, Campagna DR, McDonald A, et al. The Steap proteins are metalloreductases[J]. Blood, 2006, 108(4): 1388-1394.
[17]Ackerman CM, Lee S, Chang CJ. Analytical methods for imaging metals in biology: From Transition Metal Metabolism to Transition Metal Signaling[J]. Anal Chem, 2017, 89(1): 22-41.
[18]Maybee DV, Ink NL, Ali MAM. Novel roles of MT1MMP and MMP2: Beyond the extracellular milieu[J]. Int J Mol Sci, 2022, 23(17): 9513.
[19]Cobine PA, Moore SA, Leary SC. Getting out what you put in: Copper in mitochondria and its impacts on human disease[J]. Biochim Biophys Acta Mol Cell Res, 2021, 1868(1): 118867.
[20]Kaler SG. ATP7Arelated copper transport diseasesemerging concepts and future trends[J]. Nat Rev Neurol, 2011, 7(1): 15-29.
[21]Ackerman CM, Chang CJ. Copper signaling in the brain and beyond[J]. J Biol Chem, 2018, 293(13): 4628-4635.
[22]Kim BE, Nevitt T, Thiele DJ. Mechanisms for copper acquisition, distribution and regulation[J]. Nat Chem Biol, 2008, 4(3): 176-185.
[23]De Feyter S, Beyens A, Callewaert B. ATP7Arelated copper transport disorders: A systematic review and definition of the clinical subtypes[J]. J Inherit Metab Dis, 2023, 46(2): 163-173.
[24]Czlonkowska A, Litwin T, Dusek P, et al. Wilson disease[J]. Nat Rev Dis Primers, 2018, 4(1): 21.
[25]Ge EJ, Bush AI, Casini A, et al. Connecting copper and cancer: from transition metal signalling to metalloplasia[J]. Nat Rev Cancer, 2022, 22(2): 102-113.
[26]Lopez J, Ramchandani D, Vahdat L. Copper depletion as a therapeutic strategy in cancer[J]. Met Ions Life Sci, 2019, 19(1): 1559-1836.
[27]Sung H, Ferlay J, Siegel R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
[28]ElSerag HB. Hepatocellular carcinoma[J]. N Engl J Med, 2011, 365(12): 1118-1127.
[29]RieraRomo M. COMMD1: A multifunctional regulatory protein[J]. J Cell Biochem, 2018, 119(1): 34-51.
[30]Muller P, van Bakel H, van de Sluis B, et al. Gene expression profiling of liver cells after copper overload in vivo and in vitro reveals new copperregulated genes[J]. J Biol Inorg Chem, 2007, 12(4): 495-507.
[31]Yang M, Wu X, Hu J, et al. COMMD10 inhibits HIF1α/CP loop to enhance ferroptosis and radiosensitivity by disrupting CuFe balance in hepatocellular carcinoma[J]. J Hepatol, 2022, 76(5): 1138-1150.
[32]Yang M, Wu X, Li L, et al. COMMD10 inhibits tumor progression and induces apoptosis by blocking NFκB signal and values up BCLC staging in predicting overall survival in hepatocellular carcinoma[J]. Clin Transl Med, 2021, 11(5): e403.
[33]Chen D, Cui QC, Yang H, et al. Disulfiram, a clinically used antialcoholism drug and copperbinding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity[J]. Cancer Res, 2006, 66(21): 10425-10433.
[34]Morrison BW, Doudican NA, Patel KR, et al. Disulfiram induces copperdependent stimulation of reactive oxygen species and activation of the extrinsic apoptotic pathway in melanoma[J]. Melanoma Res, 2010, 20(1): 11-20.
[35]Qiu C, Zhang X, Huang B, et al. Disulfiram, a ferroptosis inducer, triggers lysosomal membrane permeabilization by upregulating ROS in glioblastoma[J]. Onco Targets Ther, 2020, 13(1): 10631-10640.
[36]Lin J, Haffner MC, Zhang Y, et al. Disulfiram is a DNA demethylating agent and inhibits prostate cancer cell growth[J]. Prostate, 2011, 71(4): 333-343.
[37]Zhang H, Chen D, Ringler J, et al. Disulfiram treatment facilitates phosphoinositide 3kinase inhibition in human breast cancer cells in vitro and in vivo[J]. Cancer Res, 2010, 70(10): 3996-4004.
[38]Skrott Z, Mistrik M, Andersen KK, et al. Alcoholabuse drug disulfiram targets cancer via p97 segregase adaptor NPL4[J]. Nature, 2017, 552(7684): 194-199.
[39]Li Y, Wang LH, Zhang HT, et al. Disulfiram combined with copper inhibits metastasis and epithelialmesenchymal transition in hepatocellular carcinoma through the NFκB and TGFβ pathways[J]. J Cell Mol Med, 2018, 22(1): 439-451.
[40]Chiba T, Suzuki E, Yuki K, et al. Disulfiram eradicates tumorinitiating hepatocellular carcinoma cells in ROSp38 MAPK pathwaydependent and independent manners[J]. PLoS One, 2014, 9(1): e84807.
[41]Ren X, Li Y, Zhou Y, et al. Overcoming the compensatory elevation of NRF2 renders hepatocellular carcinoma cells more vulnerable to disulfiram/copperinduced ferroptosis[J]. Redox Biol, 2021, 46(12): 102122.
[42]Zhang G, Wang Y, Fuchs BC, et al. Improving the therapeutic efficacy of sorafenib for hepatocellular carcinoma by repurposing disulfiram[J]. Front Oncol, 2022, 12(14): 913736.
[43]Gao X, Huang H, Pan C, et al. Disulfiram/copper induces immunogenic cell death and enhances CD47 blockade in hepatocellular carcinoma[J]. Cancers (Basel), 2022, 14(19): 4715.
[44]Siegel RL, Miller KD, Fuchs HE, et al. Cancer Statistics, 2021[J]. CA Cancer J Clin, 2021, 71(1): 7-33.
[45]BurnettHartman AN, Lee JK, Demb J, et al. An update on the epidemiology, molecular characterization, diagnosis, and screening strategies for earlyonset colorectal cancer[J]. Gastroenterology, 2021, 160(4): 1041-1049.
[46]Yelorda KL, Fu SJ, Owens DK. Analysis of survival among adults with earlyonset eolorectal cancer[J]. JAMA Netw Open, 2021, 4(6): e2112878.
[47]GarcíaAlfonso P, Muoz Matín AJ, Morn LO, et al. Oral drugs in the treatment of metastatic colorectal cancer[J]. Ther Adv Med Oncol, 2021, 13: 17588359211009001.
[48]McQuade RM, Stojanovska V, Bornstein JC, et al. Colorectal cancer chemotherapy: The evolution of treatment and new approaches[J]. Curr Med Chem, 2017, 24(15): 1537-1557.
[49]Rad AH, AghebatiMaleki L, Kafil HS, et al. Molecular mechanisms of postbiotics in colorectal cancer prevention and treatment[J]. Crit Rev Food Sci Nutr, 2021, 61(11): 1787-1803.
[50]Rottenberg S, Disler C, Perego P. The rediscovery of platinumbased cancer therapy[J]. Nat Rev Cancer, 2021, 21(1): 37-50.
[51]Huang D, Savage SR, Calinawan AP, et al. A highly annotated database of genes associated with platinum resistance in cancer[J]. Oncogene, 2021, 40(46): 6395-6405.
[52]Zhou J, Kang Y, Chen L, et al. The drugresistance mechanisms of five platinumbased antitumor agents[J]. Front Pharmacol, 2020, 11(20): 343.
[53]Lukanovic D, Herzog M, Kobal B, et al. The contribution of copper efflux transporters ATP7A and ATP7B to chemoresistance and personalized medicine in ovarian cancer[J]. Biomed Pharmacother, 2020, 129(12): 110401.
[54]Li YQ, Yin JY, Liu ZQ, et al. Copper efflux transporters ATP7A and ATP7B: Novel biomarkers for platinum drug resistance and targets for therapy[J]. IUBMB Life, 2018, 70(3): 183-191.
[55]Petruzzelli R, Polishchuk RS. Activity and trafficking of coppertransporting ATPases in tumor development and defense against dlatinumbased drugs[J]. Cells, 2019, 8(9): 1080.
[56]Lai YH, Kuo C, Kuo MT, et al. Modulating chemosensitivity of tumors to platinumbased antitumor drugs by transcriptional regulation of copper homeostasis[J]. Int J Mol Sci, 2018, 19(5): 1486.
[57]Shanbhag V, JasmerMcDonald K, Zhu S, et al. ATP7A delivers copper to the lysyl oxidase family of enzymes and promotes tumorigenesis and metastasis[J]. Proc Natl Acad Sci U S A, 2019, 116(14): 6836-6841.
[58]Zhou Y, Zhang Q, Wang M, et al. Effective delivery of siRNAloaded nanoparticles for overcoming oxaliplatin resistance in colorectal cancer[J]. Front Oncol, 2022, 12: 827891.
[59]Nagai M, Vo NH, Shin OL, et al. The oncology drug elesclomol selectively transports copper to the mitochondria to induce oxidative stress in cancer cells[J]. Free Radic Biol Med, 2012, 52(10): 2142-2150.
[60]Gao W, Huang Z, Duan J, et al. Elesclomol induces copperdependent ferroptosis in colorectal cancer cells via degradation of ATP7A[J]. Mol Oncol, 2021, 15(12): 3527-3544.
[61]Van Cutsem E, Sagaert X, Topal B, et al. Gastric cancer[J]. Lancet, 2016, 388(10060): 2654-2664.
[62]Wang L, Chai X, Wan R, et al. Disulfiram chelated with copper inhibits the growth of gastric cancer cells by modulating stress response and Wnt/βcatenin signaling[J]. Front Oncol, 2020, 10: 595718.
[63]Ni M, Solmonson A, Pan C, et al. Functional assessment of lipoyltransferase1 deficiency in cells, mice, and humans[J]. Cell Rep, 2019, 27(5): 1376-1386.
[64]Liu Y, Luo G, Yan Y, et al. A pancancer analysis of copper homeostasisrelated gene lipoyltransferase 1: Its potential biological functions and prognosis values[J]. Front Genet, 2022, 13(18): 1038174.
[65]Abbas G, Krasna M. Overview of esophageal cancer[J]. Ann Cardiothorac Surg, 2017, 6(2): 131-136.
[66]Li ZH, Lu X, Li SW, et al. Expression of ATP7A in esophageal squamous cell carcinoma (ESCC) and its clinical significance[J]. Int J Clin Exp Pathol, 2019, 12(9): 3521-3525.
[67]De Luca A, Barile A, Arciello M, et al. Copper homeostasis as target of both consolidated and innovative strategies of antitumor therapy[J]. J Trace Elem Med Biol, 2019, 24(55): 204-213. |